Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials

Treatment of breast cancer patients by neoadjuvant systemic therapy has traditionally been used to treat locally advanced inoperable and inflammatory cancers or preceding breast conserving surgery [1]. A recent pooled analysis from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) international working group demonstrated that pathologic complete responses (pCR) are correlated with better long term outcomes (event free survival and overall survival [OS]). This was particularly true for the more aggressive breast cancer subtypes (i.e.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qqftyz
via IFTTT